Latest news with #Clarion
The Star
15-07-2025
- Health
- The Star
Singapore researchers get S$25mil grant to screen, treat lung cancer in Asian patients
SINGAPORE: Researchers in Singapore have received a S$25 million grant to work on tackling lung cancer in Asian patients across all stages – from risk prediction and early detection of those who are at risk, to personalised treatments of patients at more advanced stages of the illness. They want to gain a deeper understanding of why the disease – the deadliest cancer globally and one that kills three people each day in Singapore – behaves differently in Asian patients. Unlike in Western countries, where lung cancer is mainly linked to smoking, nearly half of Singapore's lung cancer patients have never smoked. Many have non-small cell lung cancer, a type of the cancer that is often driven by mutations in a gene known as the EGFR. While the advent of targeted therapies in the past two decades have improved survival rates, most patients develop drug resistance within nine to 15 months, causing relapse. Even early-stage patients face relapse risks after surgery. The question is why. The $25 million grant comes from the Ministry of Health's National Medical Research Council. It establishes the project called Clarion, which stands for Conquering Lung Cancer Across All Stages With Research And Innovation. Clarion will build on more than a decade of research undertaken by a multidisciplinary team led by the National Cancer Centre Singapore (NCCS). The team also includes researchers from A*Star and the National University Cancer Institute, Singapore. At a media briefing at NCCS on July 15, Associate Professor Daniel Tan, a senior consultant in NCCS' Division of Medical Oncology, said lung cancer is a major challenge because some 60 per cent of cases are picked up in the late stages of the disease. Until now, it is not yet clear which group of people is at higher risk of having lung cancer, apart from those who have a family history. Studies elsewhere have also shown that pollution can be one of the non-smoking-related triggers of lung cancer, he said. The researchers want to find out who is at risk of the cancer in order to identify the right groups for screening, as well as find out which groups will progress to having more severe disease, and which ones will not, said Associate Professor Tam Wai Leong, deputy executive director of A*Star Genomic Institute of Singapore. Around two years ago, the national lung cancer research group launched Solstice, Singapore's first local lung cancer screening study to screen family members of lung cancer patients using low-dose CT scans. The new grant will enable them to expand this study. A screening study done in Taiwan found that about 2 per cent of 12,000 non-smokers who were screened had lung cancer. The Taiwan findings suggested that a family history of lung cancer among first-degree relatives significantly increases the risk of lung cancer. While the results of Singapore's screening programme are not ready, the lung cancer research team has achieved other milestones. These include discovering new biomarkers explaining drug resistance, and introducing comprehensive molecular profiling for lung cancer patients, allowing doctors to tailor treatments based on the genetic and molecular characteristics of their cancer. The group also set up Singapore's first multidisciplinary lung cancer clinic, where specialists collaborate to design personalised treatment plans for complex cases. The team's research serves up hope to Asians, particularly those who have never smoked but are at risk of lung cancer – like homemaker Tiffany Khor, 46. She did not notice any symptoms of the disease until she started experiencing breathlessness and a persistent cough following the birth of her second child 10 years ago. An X-ray showed that her entire left lung was filled with fluid and that she had low oxygen levels. At that point, she was told that she had Stage 3B lung cancer had that spread to her diaphragm. Tiffany Khor and her husband Josh Yong. She started experiencing breathlessness and a persistent cough following the birth of her second child 10 years ago. Khor stopped her chemotherapy treatment after only two sessions. 'I didn't know how long I would live, so I decided not to waste any more time undergoing treatment. I wanted to spend the rest of my time with my children,' she told the media at NCCS. After undergoing genomic and molecular testing, she was found to have ALK-positive non-small cell lung cancer, which could be treated using targeted therapy. However, she decided to seek alternative therapy, until early 2016 when she was too weak to decline treatment. At NCCS, scans showed that her cancer had spread to her brain, which meant her cancer had progressed to Stage 4. She went on targeted therapy and had home hospice care. In late 2023, when scans showed that her cancer spread to the lining of her brain and spinal cord, her husband Josh Yong was desperate for a solution. He researched different clinical trials and came across the drug NVL-655 which had just been cleared by the FDA for clinical trials in the United States in May 2024. From her oncologist, Yong found out that Singapore was one of the sites in a multi-country trial for the oral chemotherapy drug and got her on the ALKOVE-1 trial in June 2024. Results have been very positive, with scans showing that the tumours in Khor's spine and traces of the cancer from her brain lining have gone. Her cancer is now under control. Yong said his wife has never been better mentally and physically since she started struggling with the cancer. - The Straits Times/ANN
Straits Times
15-07-2025
- Health
- Straits Times
Researchers get $25m grant to screen, treat lung cancer in Asian patients
A team of clinicians and scientists from the National Cancer Centre Singapore have been awarded a $25 million grant. SINGAPORE - Researchers here have received a $25 million grant to work on tackling lung cancer in Asian patients across all stages – from risk prediction and early detection of those who are at risk, to personalised treatments of patients at more advanced stages of the illness. They want to gain a deeper understanding of why the disease – the deadliest cancer globally and one that kills three people each day in Singapore – behaves differently in Asian patients. Unlike in Western countries where lung cancer is mainly linked to smoking, nearly half of Singapore's lung cancer patients have never smoked. Many have non-small cell lung cancer, a type of the cancer that is often driven by mutations in a gene known as the EGFR. While the advent of targeted therapies in the past two decades have improved survival rates , most patients develop drug resistance within nine to 15 months, causing relapse. Even early-stage patients face relapse risks after surgery. The question is why. The $25 million grant comes from the Ministry of Health's National Medical Research Council. It establishes the project called Clarion, which stands for Conquering Lung Cancer Across All Stages With Research And Innovation. Clarion will build on more than a decade of research undertaken by a multidisciplinary team led by the National Cancer Centre Singapore (NCCS). The team also includes researchers from A*Star and the National University Cancer Institute, Singapore. At a media briefing at NCCS on July 15, Associate Professor Daniel Tan, a senior consultant in NCCS' Division of Medical Oncology, said lung cancer is a major challenge because some 60 per cent of cases are picked up in the late stages of the disease . Top stories Swipe. Select. Stay informed. Business MAS records net profit of $19.7 billion, fuelled by investment gains Business Singapore financial sector growth doubles in 2024, assets managed cross $6 trillion in a first: MAS Singapore $3b money laundering case: MinLaw acts against 4 law firms and 1 lawyer over seized properties Singapore Man charged with attempted murder of woman at Kallang Wave Mall Singapore Ex-cleaner jailed over safety lapses linked to guard's death near 1-Altitude rooftop bar Singapore SJI International resumes overseas trips amid ongoing probe into student's death in Maldives in 2024 Singapore Sengkang-Punggol LRT gets 15.8 per cent capacity boost with new trains Singapore 'Nobody deserves to be alone': Why Mummy and Acha have fostered over 20 children in the past 22 years Until now, it is not yet clear which group of people is at higher risk of having lung cancer, apart from those who have a family history. Studies elsewhere have also shown that pollution can be one of the non-smoking-related triggers of lung cancer, he said. The researchers want to find out who is at risk of the cancer in order to identify the right groups for screening, as well as find out which groups will progress to having more severe disease, and which ones will not, said Associate Professor Tam Wai Leong, deputy executive director of A*Star Genomic Institute of Singapore. Around two years ago, the national lung cancer research group launched Solstice, Singapore's first local lung cancer screening study to screen family members of lung cancer patients using low-dose CT scans. The new grant will enable them to expand this study. A screening study done in Taiwan found that about 2 per cent of 12,000 non-smokers who were screened had lung cancer. The Taiwan findings suggested that a family history of lung cancer among first-degree relatives significantly increases the risk of lung cancer. While the results of Singapore's screening programme are not ready, the lung cancer research team has achieved other milestones. These include discovering new biomarkers explaining drug resistance, and introducing comprehensive molecular profiling for lung cancer patients, allowing doctors to tailor treatments based on the genetic and molecular characteristics of their cancer. The group also set up Singapore's first multidisciplinary lung cancer clinic, where specialists collaborate to design personalised treatment plans for complex cases. The team's research serves up hope to Asians, particularly those who have never smoked but are at risk of lung cancer – like homemaker Tiffany Khor, 46 . She did not notice any symptoms of the disease until she started experiencing breathlessness and a persistent cough following the birth of her second child 10 years ago. An X-ray showed that her entire left lung was filled with fluid and that she had low oxygen levels. At that point, she was told that she had Stage 3B lung cancer had that spread to her diaphragm. Ms Tiffany Khor and her husband Josh Yong. She started experiencing breathlessness and a persistent cough following the birth of her second child 10 years ago. ST PHOTO: LIM YAOHUI Ms Khor stopped her chemotherapy treatment after only two sessions. 'I didn't know how long I would live, so I decided not to waste any more time undergoing treatment. I wanted to spend the rest of my time with my children,' she told the media at NCCS. After undergoing genomic and molecular testing, she was found to have ALK-positive non-small cell lung cancer, which could be treated using targeted therapy. However, she decided to seek alternative therapy, until early 2016 when she was too weak to decline treatment. At NCCS, scans showed that her cancer had spread to her brain, which meant her cancer had progressed to Stage 4. She went on targeted therapy and had home hospice care. In late 2023, when scans showed that her cancer spread to the lining of her brain and spinal cord, her husband Josh Yong was desperate for a solution. He researched different clinical trials and came across the drug NVL-655 which had just been cleared by the FDA for clinical trials in the United States in May 2024. From her oncologist, Mr Yong found out that Singapore was one of the sites in a multi-country trial for the oral chemotherapy drug and got her on the ALKOVE-1 trial in June 2024. Results have been very positive, with scans showing that the tumours in Ms Khor's spine and traces of the cancer from her brain lining have gone. Her cancer is now under control. Mr Yong said his wife has never been better mentally and physically since she started struggling with the cancer.
Business Standard
17-06-2025
- Automotive
- Business Standard
Maruti Suzuki India launches 2025 Grand Vitara S-CNG
With Premium Features Maruti Suzuki India has launched the launch of the 2025 Grand Vitara S-CNG starting at Rs. 13.48 lakh**. The 2025 Grand Vitara S-CNG is powered by the Next-Gen K-series 1.5-litre, Dual Jet, Dual VVT engine, offering a fuel-efficiency of 26.6 km/kg#. A multi-product offering, the Grand Vitara is available with a wide range of environment-friendly powertrain technologies including S-CNG, Strong Hybrid and ALLGRIP SELECT 4x4. The 2025 Grand Vitara S-CNG offers a wide range of features such as Auto Purify with PM 2.5 Display, 22.86cm (9) SmartPlay Pro+ Entertainment System with Wireless Connectivity and Steering Mounted Audio Controls, Premium Sound System by Clarion~, Tyre Pressure Monitoring System, Rear View Camera, Wireless Charging Dock, Ventilated Front Seats, Automatic Climate Control, Rear AC Vents, Reclining Rear Seats with 60:40 split, Keyless Entry With Engine Push Start/Stop Button, Auto-Folding ORVMs, Suzuki Connect and more.
Hindustan Times
17-06-2025
- Automotive
- Hindustan Times
2025 Maruti Suzuki Grand Vitara S-CNG launched, gets new features and 6 airbags
Maruti Suzuki Grand Vitara is offered with a petrol, a hybrid and a CNG powertrain. Check Offers Maruti Suzuki India Limited has launched the 2025 Grand Vitara S-CNG in the Indian market. The prices start at ₹ 13.48 lakh ex-showroom for the Delta CNG variant, whereas the Zeta CNG trim costs ₹ 15.62 lakh ex-showroom. The updated model comes with new features and safety equipment as well. 2025 Maruti Suzuki Grand Vitara CNG: What's new? For 2025, as standard there are six airbags, Electronic Stability Program, ABS with EBD, front and rear disc brakes and more. Maruti is also offering hill hold assist and ISOFIX child seat mounts. In terms of features, the 2025 Grand Vitara CNG is equipped with Auto Purify with PM 2.5 Display, Premium Sound System by Clarion~, Wireless Charging Dock, Ventilated Front Seats, Rear Door Sunshades, R17 Alloy Wheels and tyre pressure monitoring system among others. Other features on offer are a SmartPlay Pro+ Entertainment System with Wireless Connectivity and Steering Mounted Audio Controls. There is also reclining seats with 60:40 split, keyless entry with push button to start/stop the engine, auto folding ORVMs, Suzuki Connect and more. Also Read : Maruti Suzuki inaugurates India's largest automotive railway siding at its Manesar plant 2025 Maruti Suzuki Grand Vitara CNG: Specs The 2025 Grand Vitara S-CNG is powered by the Next-Gen K-series 1.5-litre, Dual Jet, Dual VVT petrol engine that is capable of producing 102 bhp of max power and a peak torque output of 136 Nm. While running on CNG, the power drops to 87 bhp and 121.5 Nm. It comes mated to a 6-speed gearbox only. The company is claiming a fuel economy of 26.6 km/kg. Commenting on the launch, Mr. Partho Banerjee, Senior Executive Officer, Marketing and Sales, Maruti Suzuki India Limited, said, 'The new 2025 Grand Vitara S-CNG offers a range of new convenience & safety alongside the introduction of 6 airbags as standard. Powered by our Next-Gen K-series 1.5-litre Dual Jet Dual VVT engine, it delivers remarkable fuel-efficiency, without compromising on its exhilarating SUV drive experience. We are confident that the new Grand Vitara S-CNG will continue to win the hearts of customers with its robust safety and commendable efficiency." Also Read : How hybrids could be the bridge to EV adoption? Grand Vitara becomes fastest-SUV to record 3 lakh sales Maruti Suzuki India Limited recently declared that it has sold more than 3,00,000 units of the Grand Vitara in the Indian market. This achievement was reached in merely 32 months, setting a record in the SUV category. The Strong Hybrid variants of the Grand Vitara were the primary contributors to the growth in FY24-25, showcasing a 43 percent year-on-year increase. Additionally, the SUV is offered with a mild-hybrid powertrain. Check out Upcoming Cars in India 2024, Best SUVs in India. First Published Date: 17 Jun 2025, 12:26 PM IST
NDTV
17-06-2025
- Automotive
- NDTV
2025 Maruti Suzuki Grand Vitara S-CNG Gets Safer, 6 Airbags Now Standard
2025 Maruti Suzuki Grand Vitara S-CNG Gets Safer, 6 Airbags Now Standard Maruti Suzuki India Limited (MSIL) has now announced the launch of the 2025 Grand Vitara S-CNG starting at Rs. 13.48 lakh (ex-showroom). The 2025 Grand Vitara S-CNG is powered by the Next-Gen K-series 1.5-litre, Dual Jet, Dual VVT engine, offering a fuel efficiency of 26.6 km/kg. A multi-product offering, the Grand Vitara is available with a wide range of environment-friendly powertrain technologies, including S-CNG, Strong Hybrid, and all-grip select 4x4. Commenting on the launch, Mr. Partho Banerjee, Senior Executive Officer, Marketing and Sales, Maruti Suzuki India Limited, said- "The new 2025 Grand Vitara S-CNG offers a range of new convenience & safety alongside the introduction of 6 airbags as standard. Powered by our Next-Gen K-series 1.5-litre Dual Jet Dual VVT engine, it delivers remarkable fuel-efficiency, without compromising on its exhilarating SUV drive experience. We are confident that the new Grand Vitara S-CNG will continue to win the hearts of customers with its robust safety and commendable efficiency." 2025 Maruti Suzuki Grand Vitara S-CNG The brand also claims that the new Grand Vitara S-CNG offers comprehensive safety for all occupants, with 6 airbags offered as standard. This is further complemented by a range of safety features including Electronic Stability Program+ with Hill Hold Assist, Anti-lock Braking System (ABS) with Electronic Brakeforce Distribution (EBD), front and rear disc brakes, ISOFIX child seat restraint system, and more. The 2025 Grand Vitara S-CNG offers a wide range of features such as auto purify with PM 2.5 display, 22.86cm (9") SmartPlay Pro+ entertainment system with wireless connectivity and steering mounted audio controls, premium sound system by Clarion, tyre pressure monitoring system, rear view camera, wireless charging dock, ventilated front seats, automatic climate control, rear AC vents, reclining rear seats with 60:40 split, keyless entry with engine push start/stop button, auto-folding ORVMs, Suzuki Connect and more. The 2025 Maruti Suzuki Grand Vitara gets two CNG variants- the Delta CNG, priced at Rs 13.48 lakh (ex-showroom), and the Zeta CNG, available at Rs 15.62 lakh (ex-showroom).
